Wolfe Research Upgrades Oruka Therapeutics (NASDAQ:ORKA) to Strong-Buy

Posted by Trevor Kearing on Feb 5th, 2025

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) was upgraded by stock analysts at Wolfe Research to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

A number of other research firms also recently commented on ORKA. Stifel Nicolaus started coverage on Oruka Therapeutics in a research note on Friday, October 11th. They issued a “buy” rating and a $49.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research note on Friday, December 20th. Finally, Wedbush reissued an “outperform” rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Oruka Therapeutics has a consensus rating of “Buy” and a consensus price target of $39.86.

Check Out Our Latest Stock Analysis on ORKA

Oruka Therapeutics Stock Up 3.7 %

ORKA opened at $14.21 on Monday. Oruka Therapeutics has a one year low of $10.95 and a one year high of $53.88. The stock has a fifty day moving average price of $18.09. The company has a market cap of $497.35 million, a P/E ratio of -2.27 and a beta of 0.77.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC purchased a new position in shares of Oruka Therapeutics during the third quarter valued at $114,763,000. RTW Investments LP purchased a new position in shares of Oruka Therapeutics during the third quarter valued at $45,359,000. Franklin Resources Inc. purchased a new position in shares of Oruka Therapeutics during the third quarter valued at $17,661,000. Braidwell LP purchased a new position in shares of Oruka Therapeutics during the third quarter valued at $12,640,000. Finally, Great Point Partners LLC purchased a new position in shares of Oruka Therapeutics during the third quarter valued at $12,614,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

(Get Free Report)

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.